← All companies ← CPF Manual CPK → ← CORT Pharmaceuticals CPRX →
CPHI, China Pharma Holdings Inc.
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
We, through Helpson, are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China (the "PRC").
The majority of Helpson's pharmaceutical products are sold on a prescription basis and all of them have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA", formerly China Food and Drug Administration, CFDA) based upon demonstrated safety and efficacy.
The business
What it sells, where the money comes from, the kind of company it is.
Next report By 11/13 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~45 days after · the wire records it on arrival
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
- What moves the needle
- Operating margin has run around −65% through the cycle on a 8.6% gross margin, the operating line deeply negative — so the lever is the path to a margin at all: revenue growth against the cost curve and the cash runway, not the level of a margin that isn't there yet. Inventory runs near 39% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −29%, above 15% in 0 of 10 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
Revenue down 7.5% year over year
figures computed from the filing's XBRL
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMJun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $16M | $13M | $12M | $11M | $11M | $10M | $8M | $7M | $5M | $4M | $4M | RevenueRevenue |
| $3M | $2M | $2M | $1M | $2M | $349K | ($494K) | ($281K) | ($2M) | ($132K) | $460K | Gross profitGross prof. |
| 21% | 19% | 16% | 14% | 18% | 4% | −6% | −4% | −44% | −3% | 12% | Gross marginGross mgn |
| 15% | 15% | 16% | 21% | 17% | 17% | 23% | 21% | 39% | 59% | 105% | SG&A / revenueSG&A/rev |
| 2% | 1% | 1% | 2% | 3% | 3% | 2% | 3% | 6% | 7% | 9% | R&D / revenueR&D/rev |
| ($8M) | ($19M) | ($10M) | ($20M) | ($3M) | ($3M) | ($4M) | ($3M) | ($5M) | ($3M) | ($4M) | Operating incomeOp. inc. |
| −52.4% | −141.4% | −84.7% | −186.8% | −23.7% | −29.7% | −43.8% | −39.2% | −101.3% | −78.2% | −111.8% | Operating marginOp. mgn |
| ($9M) | ($19M) | ($11M) | ($21M) | ($3M) | ($3M) | ($4M) | ($3M) | ($5M) | ($3M) | — | Pretax incomePretax |
| ($9M) | ($19M) | ($11M) | ($21M) | ($3M) | ($3M) | ($4M) | ($3M) | ($5M) | ($3M) | ($4M) | Net incomeNet inc. |
| Cash flow & returns | |||||||||||
| $3M | $841K | $2M | $608K | ($42K) | ($250K) | ($410K) | ($700K) | ($406K) | $148K | ($140K) | Operating cash flowOp. cash |
| $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | Depreciation & amortizationD&A |
| $9M | $17M | $9M | $18M | $145K | $62K | $863K | ($375K) | $2M | $2M | $1M | Working capital & otherWC & other |
| $193K | $136K | $51K | $136K | $867K | $438K | $402K | $12K | $38K | $59K | $59K | CapexCapex |
| 1.2% | 1.0% | 0.4% | 1.2% | 8.0% | 4.5% | 5.0% | 0.2% | 0.8% | 1.4% | 1.5% | Capex / revenueCapex/rev |
| $3M | $705K | $2M | $472K | ($910K) | ($688K) | ($812K) | ($711K) | ($444K) | $89K | ($200K) | Owner earningsOwner earn. |
| 17.4% | 5.3% | 14.8% | 4.3% | −8.4% | −7.1% | −10.0% | −10.1% | −9.8% | 2.1% | −5.1% | Owner earnings marginOE mgn |
| $3M | $705K | $2M | $472K | ($910K) | ($688K) | ($812K) | ($711K) | ($444K) | $89K | ($200K) | Free cash flowFCF |
| 17.4% | 5.3% | 14.8% | 4.3% | −8.4% | −7.1% | −10.0% | −10.1% | −9.8% | 2.1% | −5.1% | Free cash flow marginFCF mgn |
| ($193K) | ($136K) | ($51K) | ($136K) | ($867K) | ($438K) | ($402K) | ($12K) | ($292K) | ($137K) | — | Investing cash flowInv. cash |
| ($6M) | ($1M) | ($2M) | ($2M) | $624K | $5M | ($2M) | $73K | ($34K) | ($294K) | — | Financing cash flowFin. cash |
| ($264K) | $140K | ($134K) | ($19K) | $58K | ($8K) | ($248K) | $32K | ($65K) | $1K | — | Exchange-rate effectFX |
| ($4M) | ($636K) | ($279K) | ($1M) | ($227K) | $4M | ($3M) | ($606K) | ($797K) | ($282K) | — | Change in cashΔ cash |
| -11% | -29% | -23% | -129% | -17% | -35% | -124% | -29% | -43% | -11% | -10% | ROICROIC |
| -16% | -45% | -36% | -224% | -36% | -56% | -93% | -41% | -61% | -14% | -12% | Return on equityROE |
| −16% | −45% | −36% | −224% | −36% | −56% | −93% | −41% | −61% | −14% | −12% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $3M | $2M | $1M | $1M | $958K | $5M | $2M | $1M | $627K | $345K | $305K | Cash & investmentsCash+inv |
| $4M | $2M | $917K | $635K | $502K | — | $422K | $504K | $232K | $241K | $182K | ReceivablesReceiv. |
| $7M | $6M | $5M | $4M | $4M | $3M | $3M | $4M | $2M | $2M | $1M | InventoryInvent. |
| $3M | $1M | $1M | $1M | $1M | $927K | $667K | $966K | $225K | $891K | $734K | Accounts payablePayables |
| $8M | $8M | $5M | $3M | $3M | $2M | $3M | $3M | $2M | $972K | $810K | Operating working capitalOper. WC |
| $18M | $12M | $9M | $6M | $5M | $9M | $6M | $6M | $3M | $2M | $2M | Current assetsCur. assets |
| $10M | $9M | $10M | $10M | $11M | $11M | $13M | $7M | $5M | $7M | $8M | Current liabilitiesCur. liab. |
| 1.7× | 1.3× | 0.9× | 0.6× | 0.5× | 0.9× | 0.5× | 0.9× | 0.7× | 0.3× | 0.3× | Current ratioCurr. ratio |
| $25M | $24M | $19M | $16M | $16M | $13M | $10M | $7M | $5M | $4M | — | Net PP&ENet PP&E |
| $79M | $60M | $45M | $22M | $21M | $23M | $18M | $16M | $15M | $31M | $45M | Total assetsAssets |
| — | $9M | $7M | $4M | $5M | $5M | — | $1M | $1M | — | — | Total debtDebt |
| — | $7M | $5M | $3M | $4M | $391K | — | ($12K) | $764K | — | — | Net debt / (cash)Net debt |
| -9.6× | -34.6× | -23.2× | -63.4× | -8.8× | -5.3× | -8.2× | -90.0× | -167.8× | -118.8× | -136.3× | Interest coverageInt. cov. |
| $20M | $17M | $15M | $13M | $13M | $17M | $13M | $9M | $7M | $8M | — | Total liabilitiesTotal liab. |
| $59M | $43M | $30M | $9M | $8M | $6M | $4M | $7M | $8M | $23M | $36M | Shareholders’ equityEquity |
| — | $14M | $6M | $17M | — | — | — | — | — | — | $17M | Goodwill written downGW imp. |
| Per share | |||||||||||
| 1.1M | 1.1M | 1.1M | 1.1M | 1.1M | 1.2M | 1.1M | 3.4M | 1.7M | 4.3M | 34.1M | Shares out (diluted)Shares |
| $14.29 | $12.13 | $11.32 | $10.03 | $9.96 | $8.36 | $7.71 | $2.07 | $2.59 | $0.97 | $0.11 | Revenue / shareRev/sh |
| $-8.43 | $-17.69 | $-9.87 | $-19.00 | $-2.63 | $-2.95 | $-3.78 | $-0.91 | $-2.71 | $-0.74 | $-0.13 | EPS (diluted)EPS |
| $2.48 | $0.65 | $1.68 | $0.43 | $-0.83 | $-0.60 | $-0.77 | $-0.21 | $-0.25 | $0.02 | $-0.01 | Owner earnings / shareOE/sh |
| $2.48 | $0.65 | $1.68 | $0.43 | $-0.83 | $-0.60 | $-0.77 | $-0.21 | $-0.25 | $0.02 | $-0.01 | Free cash flow / shareFCF/sh |
| $0.18 | $0.13 | $0.05 | $0.12 | $0.80 | $0.38 | $0.38 | $0.00 | $0.02 | $0.01 | $0.00 | Cap. spending / shareCapex/sh |
| $54.07 | $39.53 | $27.72 | $8.48 | $7.34 | $5.22 | $4.08 | $2.20 | $4.44 | $5.30 | $1.06 | Book value / shareBVPS |
Share counts before 2022 are restated ×1/40 for a stock split, so per-share figures sit on one basis.
The diluted share count moved ×3.22 into 2023 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1/1.94 into 2024 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×2.46 into 2025 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×7.94 into TTM — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | −25.9%/yr | −37.3%/yr |
| Owner earnings / share | −41.2%/yr | — |
| Capital spending / share | −24.7%/yr | −55.5%/yr |
| Book value / share | −22.7%/yr | −6.3%/yr |
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned a $3M loss into $89K of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | ($3M) | ($5M) | ($3M) | ($4M) | ($3M) |
| Depreciationnon-cash charge added back | +$652K | +$2M | +$3M | +$3M | +$3M |
| Amortization of intangible assetsnon-cash charge added back; the purchase price of past acquisitions, expensed over time | +$852K | +$447K | +$224K | +$37K | +$38K |
| Working capital & othertiming of cash in and out, other non-cash items | +$2M | +$2M | −$375K | +$863K | +$62K |
| Cash from operations | $148K | ($406K) | ($700K) | ($410K) | ($250K) |
| Capital expenditurecash put back in to keep running and to grow | −$59K | −$38K | −$12K | −$402K | −$438K |
| Owner earnings | $89K | ($444K) | ($711K) | ($812K) | ($688K) |
| Owner-earnings marginowner earnings ÷ revenue | 2% | -10% | -10% | -10% | -7% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? -118.8×Does not cover its interestOperating income ($3M) ÷ interest expense $27K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net debt against an operating lossCash $345K − debt $5M
What this means
Netting $345K of cash and short-term investments against $5M of debt leaves $5M owed, with no operating profit this year to measure it against — understand that combination before anything else about the company. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 21 + DIO 138 − DPO 76 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle10-yr median, range -129%–-11%; -9% latest = NOPAT ($3M) ÷ invested capital $28MIndustry peers: median -128%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran -9% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Positive this year, negative across the cyclelatest $89K = operating cash $148K − maintenance capex $59K (positive this year), after an earlier loss stretch (10-yr median -2%)Industry peers: median -326%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 2% of revenue this year, a -2% median across 10 years.
- Loss, but cash-generativeNet income ($3M) · cash from operations $148K
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.04×HarvestingCapex $59K ÷ depreciation & amortization as filed $2M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 0 of 4 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $4M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity MissCurrent ratio ≥ 2× · 0.32×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt MissDebt ≤ working capital · $5M vs ($5M) WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 10 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record —Uninterrupted dividends · no dividend line tagged in the data
What this means
An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.
- Earnings growth —Earnings +33% over the record · —
What this means
Earnings were negative early in the record, a growth rate isn't meaningful.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.09/share (latest year $-0.07), the averaged base the calculator's gate runs on, and book value is $0.53/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 0 of 10
What this means
Lost money in 10 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 0 of 7 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin −93% → −73% (3-yr avg ends)
What this means
Through the cycle the operating margin widened — about −93% early to −73% lately, median −78% — pricing power intact or improving.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Worst year 2019 · −186.8% op. margin
What this means
Operations went underwater in 2019, understand why before trusting the good years.
- How management talks about it Promotional
What this means
The record is compounding, but the filing leans on a promoter’s vocabulary rather than the per-share, return-on-capital terms an owner uses. The results back the talk here; the register is still worth noting.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Jun 30, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$305K
- Receivables$182K
- Inventory$1M
- Other current assets$158K
- Accounts payable$734K
- Other current liabilities$7M
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $5M of operating cash; how management split it reads as a reinvestor, most operating cash is plowed back into the business.
- Reinvested$2M · 51%
- Retained (debt / cash)$2M · 49%
- Source of fundingOperating cash
Operating cash covered reinvestment and returns; over the span cash and short-term investments fell $2M.
- Net change in share count3028.8%
The diluted count rose from 1M to 34M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.
- Dividend record—
No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid.
- Insider ownership6.4%
The stake all directors and executive officers hold together, per the 2025 proxy: skin in the game, the first thing Munger reads.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.
| Company | Revenuelatest FY, USD | Gross marginmedian over the record | Op. marginmedian over the record | ROICmedian over the record | Owner earn. marginmedian over the record |
|---|---|---|---|---|---|
| ACRSAclaris Therapeutics Inc. | $8M | 28% | -534.9%4y | -73% | -241%4y |
| ADAGAdagene Inc. | $8M | — | -279.5%3y | — | -204%3y |
| IMMPImmutep Limited | $7M | — | -544.6% | -183% | -445% |
| OVIDOvid Therapeutics Inc. | $7M | — | -585.2% | -64% | -410% |
| CPHIChina Pharma Holdings Inc. | $4M | 9% | -65.3% | -29% | -2% |
| ATAIAtaiBeckley Inc. | $4M | — | — | -220%2y | — |
| RADXRadiopharm Theranostics Limited | $4M | 1%1y | — | -219% | — |
| UPBUpstream Bio Inc. | $3M | — | — | -48%2y | — |
| Group median | — | 9% | -534.9% | -73% | -241% |
The price
What a price has to assume.
What the price implies
reverse-DCFChina Pharma Holdings Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
Revenue, delivered−19%/yr’20→’25
Enter a price to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Manual order: ← CPF its page in the Manual CPK →
Industry order: ← CORT the Pharmaceuticals chapter CPRX →